We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




New Genetic Forms of Neurodegeneration Discovered

By LabMedica International staff writers
Posted on 13 Feb 2014
The number of known causes for the neurodegenerative disorder known as hereditary spastic paraplegia (HSP) has been doubled. More...


HSP is characterized by progressive stiffness and contraction of the lower limbs and is associated with epilepsy, cognitive impairment, blindness and other neurological features.

Scientists at the University of California (San Diego, CA; USA) recruited a cohort of more than 50 families displaying autosomal recessive HSP, the largest such cohort assembled to date. They analyzed roughly 100 patients from this cohort using a technique called whole exome sequencing, which focuses on mapping key portions of the genome.

Whole exome sequencing was performed using the SureSelect Human All Exome Kit (Agilent Technologies, Santa Clara, CA, USA) with 100-bp paired-end read sequences generated on a HiSeq 2000 (Illumina, San Diego, CA, USA). The investigators identified a genetic mutation in almost 75% of the cases, half of which were in genes never before linked with human disease, and greatly increasing the number of mutated genes in HSP.

Joseph G. Gleeson, MD, the senior author of the study said, “After uncovering so many novel genetic bases of HSP, we were in the unique position to investigate how these causes link together. We were able to generate an 'HSP-ome,' a map that included all of the new and previously described causes.”

This ‘HSP-ome’ helped the scientists locate and validate even more genetic mutations in their patients, and indicated key biological pathways underlying HSP. They were also interested in understanding how HSP relates to other groups of disorders and they found that the ‘HSP-ome’ links HSP to other more common neurodegenerative disorders, such as Alzheimer's disease and amyotrophic lateral sclerosis.

The authors concluded that the principle that integrating family-based gene discovery together with prior knowledge can facilitate the identification of biological pathways and processes disrupted in disease. Furthermore, this mode of analysis should be highly useful in the future to aid in the validation of private mutations in genes found in single families, to identify novel candidate genes and pathways, and for the discovery of potential therapeutic targets. The study was published on January 31, 2014, in the journal Science.

Related Links:

University of California San Diego 
Agilent Technologies
Illumina



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gastrointestinal Panel
Xpert® GI Panel
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.